0001439222-24-000030.txt : 20240214 0001439222-24-000030.hdr.sgml : 20240214 20240214175339 ACCESSION NUMBER: 0001439222-24-000030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240212 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gheuens Sarah CENTRAL INDEX KEY: 0001881190 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 24640978 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-8600 MAIL ADDRESS: STREET 1: 88 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20080703 4 1 wk-form4_1707951190.xml FORM 4 X0508 4 2024-02-12 0 0001439222 AGIOS PHARMACEUTICALS, INC. AGIO 0001881190 Gheuens Sarah 88 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Medical Officer 1 Common stock 2024-02-12 4 M 0 2162 0 A 34073 D Common stock 2024-02-14 4 S 0 642 25.14 D 33431 D Restricted stock units 2024-02-12 4 M 0 2162 0 D Common stock 2162 0 D Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 10, 2021. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. /s/ William Cook, as attorney-in-fact for Sarah Gheuens 2024-02-14